Composition and imaging methods for pharmacokinetic and pharmacodynamic evaluation of therapeutic delivery system
AssigneeVanderbilt University
InventorDennis E. Hallahan
Life of this patent
Estimating the term…
Abstract
A halogen-labeled gene therapy construct that includes halogen-labeled nucleic acids, methods for preparing a halogenated gene therapy construct, and methods for in vivo imaging of the same. Also provided are methods for non-invasive drug detection in a subject using a labeled antibody that recognizes a heterologous antigen conjugated to, encoded by, or otherwise associated with the drug.
Claims49
A method for preparing a halogen-labeled gene therapy construct, the method comprising:
- (a) introducing a gene therapy construct into helper cells, wherein the gene therapy construct comprises one or more nucleic acids;
- and
- (b) providing a halogen-labeled nucleotide to the helper cells, whereby a halogen-labeled gene therapy construct is prepared.
A halogen-labeled gene therapy construct comprising:
- (a) a vector;
- and
- (b) one or more nucleic acids, wherein one or more of the nucleic acids comprises a halogen-labeled nucleotide, wherein the nucleic acids are free of triplex structures, and wherein the halogen-labeled gene therapy construct can be detected in vivo.
A method for non-invasive detection in a subject of a halogen-labeled gene therapy construct, the method comprising:
- (a) administering to a subject an effective dose of a halogen-labeled gene therapy construct, wherein the construct comprises a vector and one or more nucleic acids, and wherein one or more of the nucleic acids comprises a halogen-labeled nucleotide;
- and
- (b) detecting the halogen-labeled nucleotide, wherein the detecting comprises a non-invasive detection technique.
A method for detecting a drug in a subject, the method comprising:
- (a) administering to a subject an effective dose of a drug, wherein the drug comprises a heterologous antigen;
- (b) administering to the subject an antibody that binds the heterologous antigen, wherein the antibody comprises a label that can be detected in vivo;
- and
- (c) detecting the label in vivo, whereby the drug is detected in the subject.
Dependencies are inferred from the claim text.